ClinicalTrials.gg
Active, not recruitingNCT04072458Updated Feb 24, 2025

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

A Phase 1 interventional study of L-Bcl-2 antisense oligonucleotide in Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL), sponsored by Bio-Path Holdings, Inc.. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Bio-Path Holdings, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Lymphoma, Mantle-Cell with a site in United States — 81 open to participants now, 149 under way, 7 of them phase 3. Lymphoma, Mantle-Cell · United States.

Planned enrollment
414th of 777
30 · median 35
Started
2020
with 19 others
Phase 1
313 of 905
27 open now
Primary completion
2025-04
later than 22 of 148 live
Registered
766th of 905
by date

Among the 905 studies in Lymphoma, Mantle-Cell with a site in United States, this one is the 414th largest by planned enrollment of the 777 interventional ones that give a count, is one of 20 that started in 2020, is one of 313 in phase 1, reaches primary completion later than 22 of the 148 other live ones, and was the 766th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

81 of the 905 studies in Lymphoma, Mantle-Cell with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Lymphoma, Mantle-Cell with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.

03

Conditions studied

  • Mantle Cell Lymphoma
  • Peripheral T-cell Lymphoma (PTCL)
  • Cutaneous T-cell Lymphoma (CTCL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Hodgkin Lymphoma
  • Waldenstrom Macroglobulinemia
  • DLBCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥18 years of age
  2. Patient has a ≥ 3 month
  3. Patient has disease Relapsed lymphoma: Relapsed lymphoma is disease that has responded to treatment but then returns.

    Refractory lymphoma: Failure to achieve complete response at the end of therapy or progression within 6 months from completion of therapy

  4. Included Diseases

    • DLBCL, including transformed lymphoma
    • Mantle Cell Lymphoma
    • PTCL
    • CTCL
    • CLL/SLL
    • Follicular lymphoma
    • Marginal zone lymphoma
    • Hodgkin lymphoma (both classical and lymphocyte predominant)
    • Waldenströms Macroglobulinemia
  5. Must has failed or is not a candidate for available therapies with reasonable likelihood of clinical benefit, which includes FDA approved products and standard of care regimens
  6. Therapy means at least three front including Hematopoeitic Stem Cell Transplant ( and/or Chimeric Antigen Receptor (CAR) T cells, when applicable
  7. Females must be of non-, surgically sterile, , or practice adequate methods of during the study
  8. Males must agree to use an adequate method of contraception during the study
  9. (ECOG) Performance score of 0, 1, or 2
  10. Adequate hepatic and renal functions as defined by:

    • (AST) and alanine transaminase (ALT) ≤2.5 times the (ULN); and
    • Total ≤1.5 times ULN; and
    • Estimated (eGFR) of at least 50ml/min. These estimations can be calculated using the following methods:

      • Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation
      • equation
      • Modification of Diet in Renal Disease (MDRD study equation)
      • Creatinine clearance estimated by 24-hr urine collection for creatinine clearance
  11. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
  12. Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Active non-hematologic other than lymphoid malignancies treated with immuno- or chemotherapy within the previous 12 months except active non-melanoma, non-invasive skin cancer will be allowed
  2. Known, active Central Nervous System (CNS) involvement of disease requiring intrathecal therapy. Note: Patients with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening
  3. Patient eligible for high dose chemotherapy and stem cell transplant
  4. Indolent non-Hodgkin lymphoma (iNHL)
  5. Patients at high risk of Tumor Lysis Syndrome (TLS)

    a. Bulky disease i. A unidimensional lesion greater than 10 cm and/or b. Lymphocyte count greater than 25,000 per µL

  6. Receipt of any anti-cancer therapy within 14 days prior to Cycle 1 Day 1 (C1D1)
  7. Uncontrolled active, untreated, or progressive infection
  8. Receipt of any agent or on study treatment within 30 days prior to C1D1
  9. Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
  10. Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study
  11. Active infection (based on positive surface antigen [HBsAg]), infection (based on Hepatitis C Virus (HCV) positive antibody [HCV Ab]), or (HIV-1 or HIV-2, based on positive antibody)
  12. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, cardiac dysrhythmia or clinically significant baseline abnormality (e.g., >470 msec)
  13. Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or
  14. Uncontrolled seizure disorder
  15. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    BP1002 monotherapy

    L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m\^2.

    Drug: L-Bcl-2 antisense oligonucleotide

Interventions

  • DrugL-Bcl-2 antisense oligonucleotide

    There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.

    Also known as: BP1002

06

What researchers measure

Primary outcomes

  1. Identify Dose Limiting Toxicity (DLT) of BP1002

    Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  2. Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002

    Identify TEAE of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  3. Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 by identification and grading of

    Identify and grade treatment-emergent laboratory abnormalities of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  4. Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) of escalating doses of BP1002

    Collection of 12-lead EKGs at defined intervals to identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals)

    Time frame: 30 days

  5. Recommended Phase 2 dose (RP2D) of BP1002

    Determine RP2D by evaluating Maximally Tolerated Dose (MTD) data: Any Dose Limiting Toxicity (DLT) observed will trigger an expansion of a cohort from 3 to 6 patients. A second DLT at any dose level will identify the Maximum Dose. The dose below that will be the MTD.

    Time frame: 210 days

  6. Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration

    Evaluate in vivo PK of BP1002 using maximum plasma drug concentration (Cmax)

    Time frame: 30 days

  7. Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution

    Evaluate in vivo PK of BP1002 volume of distribution (Vd)

    Time frame: 30 days

  8. Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant

    Evaluate in vivo PK of BP1002 elimination rate constant

    Time frame: 30 days

  9. Determine half-life plasma pharmacokinetics (PK) of BP1002

    Evaluate in vivo PK of BP1002 half-life (t1/2)

    Time frame: 30 days

  10. Determine pharmacokinetics (PK) of BP1002

    12-lead EKG assessments will be collected and analyzed for conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) from those the EKG obtained immediately before the first BP1002 dose, and after BP1002 dose, and will mirror the time points used to collect the plasma PK assessments

    Time frame: 30 days

Secondary outcomes

  1. Determine evidence of tumor response by bone marrow aspirate

    Assess tumor response by evaluating bone marrow aspirate to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th)

    Time frame: 30 days

  2. Determine evidence of tumor response by Complete Blood Count (CBC)

    Assess tumor response by evaluating CBC measurements to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th)

    Time frame: 30 days

  3. Determine estimates for time to progression (TTP)

    Measured from treatment start date to date of progression by CBC and/or bone marrow aspirate

    Time frame: 30 days

  4. Determine estimates for progression-free survival (PFS)

    Measured from treatment start date to date of progression or death by CBC and/or bone marrow aspirate

    Time frame: 30 days

  5. Determine estimates for event-free survival (EFS)

    Measured from treatment start date to date of progression, death, or change in therapy by CBC and/or bone marrow aspirate

    Time frame: 30 days

  6. Activity of BP1002 on Bcl-2 expression in tumor samples

    Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression using patient blood samples

    Time frame: 30 days

Other outcomes

  1. Exploratory objective to correlate treatment response with cytogenetic characteristics

    Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression

    Time frame: 30 days

  2. Exploratory objective to correlate treatment response with molecular characteristics

    Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression

    Time frame: 30 days

07

Study locations

5 sites
  • Georgia Cancer Center
    Augusta, Georgia 30912, United States
  • New York Medical College / Westchester Medical Center
    Valhalla, New York 10595, United States
  • Sarah Cannon Research Institute/Tennesee Oncology
    Nashville, Tennessee 37203, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Research Center
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Apr 2025, 53 months after the start.

Of 55 industry-sponsored phase 1 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 53 months is close to that.

Counting every sponsor, half of 128 studies reached it within 61 months; a quarter within 36 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2019
First posted
Aug 28, 2019
StartActual
Nov 5, 2020
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04072458
Lead sponsor
Bio-Path Holdings, Inc.
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Nov 5, 2020
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Feb 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion